ACR-2316

ACR-2316 is a novel, internally developed small molecule dual inhibitor of WEE1 (Serine/threonine-protein kinase WEE1) and PKMYT1 (Protein kinase, membrane associated tyrosine/threonine 1), designed by Acrivon Therapeutics using their proprietary AP3 Generative Phosphoproteomics platform. The drug was rationally engineered to overcome the limitations of single-target WEE1 or PKMYT1 inhibitors and to induce potent anti-tumor activity as a single agent. Mechanistically, ACR-2316 achieves its effect through comprehensive inhibition of the G2/M cell cycle checkpoint, leading to forced mitotic entry in cancer cells with DNA damage and resulting in pro-apoptotic tumor cell death. This is mediated by potent activation of CDK1, CDK2, and PLK1 pathways downstream of its primary targets. Preclinical studies have demonstrated superior efficacy compared to benchmark inhibitors, with early Phase 1 clinical data showing approximately 25% tumor shrinkage at submaximal doses without dose-limiting toxicities. The drug is currently being evaluated in a first-in-human Phase 1 trial for advanced solid tumors[2][4][5][6][8].